Valinomycin as a potential antiviral agent against coronaviruses: A review

Autor: Dong Zhang, Hanchi Chen, Yuele Lu, Zhi Ma, Xiaolong Chen
Jazyk: angličtina
Rok vydání: 2020
Předmět:
0301 basic medicine
Antiviral agent
Middle East respiratory syndrome coronavirus
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
viruses
Drug repurposing
medicine.disease_cause
Antiviral Agents
Article
03 medical and health sciences
Valinomycin
chemistry.chemical_compound
0302 clinical medicine
medicine
Humans
Human coronavirus OC43
lcsh:QH301-705.5
lcsh:R5-920
biology
business.industry
Drug discovery
SARS-CoV-2
fungi
virus diseases
General Medicine
biology.organism_classification
Virology
COVID-19 Drug Treatment
respiratory tract diseases
Coronavirus
Drug repositioning
030104 developmental biology
Treatment Outcome
chemistry
lcsh:Biology (General)
030220 oncology & carcinogenesis
Middle East Respiratory Syndrome Coronavirus
Severe acute respiratory syndrome coronavirus
business
lcsh:Medicine (General)
Zdroj: Biomedical Journal, Vol 43, Iss 5, Pp 414-423 (2020)
Biomedical Journal
ISSN: 2319-4170
Popis: Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), have been resulting in global epidemics with heavy morbidity and mortality. Unfortunately, there are currently no specific medicines that can better treat these coronaviruses. Drug repurposing is an effective and economical strategy for drug discovery from existing drugs, natural products, and synthetic compounds. In this review, the broad-spectrum antiviral activity of valinomycin (VAL), especially its activity against coronaviruses such as SARS-CoV, MERS-CoV, human coronavirus OC43 (HCoV-OC43), were summarized, it highlights that VAL has tremendous potential for use as a novel antiviral agent against SARS-CoV-2.
Graphical abstract Image 1
Databáze: OpenAIRE
Externí odkaz: